FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:418-421 January 25, 2007 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Balch, C. M. Related Article by Morton, D. L. PubMed Citation

To the Editor: The results of the trial by Morton et al. (Sept. 28 issue)¹ involving sentinel-node biopsy in patients with melanoma do not show a survival benefit with immediate lymphadenectomy for three reasons. First, there were false positive results in the sentinel node (tiny deposits of melanoma not destined to progress to a palpable nodal recurrence, which is a surrogate measure for survival). Since there was no significant difference in survival between the study groups from the time of randomization, only 119 patients in the biopsy group would be expected to have a palpable nodal recurrence; of these patients, . . . [Full Text of this Article]

This article has been cited by other articles:

• Grange, F., Vitry, F., Granel-Brocard, F., Lipsker, D., Aubin, F., Hedelin, G., Dalac, S., Truchetet, F., Michel, C., Batard, M.-L., Baury, B., Halna, J.-M., Schmutz, J. L., Delvincourt, C., Reuter, G., Dalle, S., Bernard, P., Danzon, A. (2008). Variations in Management of Stage I to Stage III Cutaneous Melanoma: A Population-Based Study of Clinical Practices in France. Arch Dermatol 144: 629-636 [Abstract] [Full Text]  
• Kanzler, M. H. (2007). The Current Status of Evaluation and Treatment of High-Risk Cutaneous Melanoma: Therapeutic Breakthroughs Remain Elusive. Arch Dermatol 143: 785-787 [Full Text]